Innate Immune Signaling Pathways in Alzheimer's Disease

Innate Immune Signaling Pathways in Alzheimer's Disease

Overview

The innate immune system plays a dual role in Alzheimer's disease (AD): initially mounting protective responses to clear pathological protein aggregates, but ultimately driving chronic neuroinflammation that accelerates neurodegeneration. Pattern recognition receptors (PRRs) — including Toll-like receptors (TLRs), NOD-like receptors (NLRs), and cytosolic DNA sensors — detect amyloid-beta and other danger-associated molecular patterns (DAMPs), activating downstream signaling cascades involving NF-kappaB, the NLRP3 inflammasome, and the cGAS-STING pathway["heneka2015"].

Innate Immune Signaling Pathways in Alzheimer's Disease

Overview

The innate immune system plays a dual role in Alzheimer's disease (AD): initially mounting protective responses to clear pathological protein aggregates, but ultimately driving chronic neuroinflammation that accelerates neurodegeneration. Pattern recognition receptors (PRRs) — including Toll-like receptors (TLRs), NOD-like receptors (NLRs), and cytosolic DNA sensors — detect amyloid-beta and other danger-associated molecular patterns (DAMPs), activating downstream signaling cascades involving NF-kappaB, the NLRP3 inflammasome, and the cGAS-STING pathway["heneka2015"].

Genome-wide association studies (GWAS) have identified numerous AD risk loci in innate immune genes — including TREM2, CD33, INPP5D, PLCG2, ABI3, and ABCA7 — establishing neuroinflammation as a core pathogenic mechanism rather than a secondary consequence of neurodegeneration["el2017"][sims2017].

Toll-Like Receptor Signaling

TLR2 and TLR4

TLR4 is the most extensively studied innate immune receptor in AD. It recognizes fibrillar and oligomeric amyloid-beta as a DAMP, initiating MyD88-dependent signaling that activates NF-κB and MAPK pathways[li2023].

Upon amyloid-beta binding, TLR4 forms a complex with MD-2 and CD14, triggering:

• MyD88-dependent pathway: Rapid activation of NF-κB and AP-1, leading to pro-inflammatory cytokine production (TNF-alpha, IL-6, IL-1β)
• TRIF-dependent pathway: Activation of IRF3 and type I interferon production

TLR9 and Mitochondrial DNA Sensing

TLR9, an endosomal receptor that recognizes unmethylated CpG DNA, is activated by mitochondrial DNA (mtDNA) released from damaged neurons. Mitochondrial dysfunction in AD leads to mtDNA release into the cytoplasm and extracellular space, where it acts as a potent DAMP.

NLRP3 Inflammasome

The NLRP3 inflammasome is a key driver of chronic neuroinflammation in AD[heneka2015]. NLRP3 inflammasome activation requires two sequential signals:

The NLRP3 inflammasome contributes to tau pathology progression through IL-1β-mediated activation of kinases that phosphorylate tau, including GSK-3β and CDK5[ising2019].

ASC Specks and Cross-Seeding

A critical pathogenic mechanism is the discovery that ASC specks released from pyroptotic microglia cross-seed amyloid-beta in the brain[venegas2017]. ASC specks:

• Are remarkably stable and persist in the extracellular space
• Can be phagocytosed by neighboring microglia
• Act as nuclei for amyloid-beta aggregation
• Spread pathology between brain regions

cGAS-STING Pathway

The cGAS-STING pathway is a cytosolic DNA-sensing mechanism activated by cGAS, which detects double-stranded DNA in the cytoplasm. In AD, mitochondrial and nuclear DNA released from damaged neurons activates cGAS-STING, driving type I interferon (IFN-I) production[xie2022].

STING and Tau Pathology

STING activation contributes to tau pathology through interferon-mediated upregulation of kinases that phosphorylate tau, including GSK-3β and CDK5. In tauopathy mouse models, genetic deletion of STING reduces tau phosphorylation, neuroinflammation, and neurodegeneration.

STING and Microglial Dysfunction

STING activation in microglia promotes a neurotoxic inflammatory phenotype while impairing phagocytic function. The resulting type I interferon response upregulates complement components, chemokines (CXCL10, CCL2), and antigen presentation molecules (MHC-II), amplifying the broader neuroinflammatory cascade.

TREM2 Signaling

Structure and Function

TREM2 (triggering receptor expressed on myeloid cells 2) is expressed primarily on microglia and serves as a critical regulator of microglial survival, proliferation, and function. TREM2 binds amyloid-beta and lipid ligands, triggering signaling through the adaptor protein DAP12 (TYROBP)[el2017].

TREM2 Variants and AD Risk

Rare coding variants in TREM2 are associated with dramatically increased AD risk (heterozygous variants increase risk 2-4×)[el2017]. The R47H variant specifically impairs TREM2's ability to bind amyloid-beta and lipid ligands, reducing microglial activation around plaques.

Microglial States

Single-cell RNA sequencing has revealed multiple microglial states in AD[kerenshaul2017]:

• Homeostatic microglia: Present in normal brain
• Disease-associated microglia (DAM): Upregulated in AD, characterized by increased TREM2 expression and lipid metabolism genes
• IFN-responsive microglia: Upregulated type I interferon response genes

Complement System

The complement system provides innate immune defense through opsonization, inflammation, and membrane attack complex (MAC) formation. In AD, complement components C1q, C3, and C4 are significantly upregulated, particularly around amyloid plaques and degenerating synapses[hong2016].

Complement-Mediated Synapse Elimination

C1q binds to synapses in an age- and amyloid-dependent manner, initiating the classical complement cascade that culminates in C3b/iC3b deposition on synaptic membranes. Complement receptor 3 (CR3/CD11b) on microglia then mediates phagocytic removal of tagged synapses[hong2016].

Key findings:

• C1q is increased and associated with synapses before overt plaque deposition in mouse models
• Inhibition of C1q, C3, or CR3 reduces the number of phagocytic microglia at synapses
• C1q initiates the complement cascade, leading to synaptic loss

Therapeutic Implications

Precision Immunomodulation

The dual protective/destructive nature of innate immunity in AD necessitates precision approaches rather than broad immunosuppression. Multiple clinical trials of NSAIDs failed in AD, likely because these agents suppress both harmful and protective immune functions.

Current therapeutic strategies:

| Target | Approach | Stage | Status |
|--------|----------|-------|--------|
| TREM2 | Agonist antibodies (AL002, JZH6) | Phase II | Active trials |
| NLRP3 | Small molecule inhibitors | Preclinical | Development |
| C1q | Anti-C1q antibody (ANX005) | Phase II | Recruiting |
| STING | STING antagonists (H-151) | Preclinical | Proof of concept |

Biomarker-Guided Therapeutic Timing

Inflammatory biomarkers can identify patients with prominent neuroinflammation and guide therapeutic timing:

• sTREM2: Soluble TREM2, peaks during early symptomatic stages
• YKL-40: CSF marker of astrocytic inflammation
• IL-6, TNF-alpha: Pro-inflammatory cytokines in CSF
• Complement fragments (C4a, C3a): Reflect complement cascade activation

Integrated Pathway Model

Cross-References

• TREM2 Gene — Key microglial receptor and AD risk gene
• Microglia — Primary innate immune cells of the brain
• NLRP3 Inflammasome — Inflammasome pathway in AD
• cGAS-STING in Neurodegeneration
• NF-κB Signaling in Neuroinflammation
• Complement System

See Also

• Alzheimer's Disease
• Neuroinflammation
• Amyloid Cascade Hypothesis
• Microglial Phagocytosis
• All Mechanisms

References

Pathway Diagram

The following diagram shows the key molecular relationships involving Innate Immune Signaling Pathways in Alzheimer's Disease discovered through SciDEX knowledge graph analysis: